Compare Crocs, Inc. (CROX) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Quest Diagnostics Inc — how do they compare? Crocs, Inc. trades at $116.78 (market cap $5.60B), while Quest Diagnostics Inc trades at $230.78 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 4.5× Crocs, Inc.'s market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Quest Diagnostics Inc for 56 Days on average.
| CROX | DGX | |
|---|---|---|
Market Cap | $5.60B | $25.48B |
Volume | 1,026,773 | 941,866 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $247.45 |
52-Week Low | $73.39 | $173.49 |
Typical Hold Time | 96 Days | 56 Days |
Enterprise Value | $7.12B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $117.64, up 2.12% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but maintains strong fundamentals including a 10.37 P/E ratio and 42.3% ROE. Recent management commentary highlights product innovation and HEYDUDE brand repositioning as growth catalysts. Cash flow trends show consistent operational strength despite recent net income volatility.
The outlook remains cautiously optimistic with analyst consensus targeting $136.78 (16% upside). Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification. The combination of attractive valuation, strong profitability metrics, and positive earnings surprises supports potential long-term appreciation despite near-term technical weakness.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
